User profiles for C.G. Hadjipanayis

Constantinos G. Hadjipanayis, MD, Ph.D.

University of Pittsburgh School of Medicine
Verified email at upmc.edu
Cited by 12397

Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma

EG Van Meir, CG Hadjipanayis… - CA: a cancer journal …, 2010 - Wiley Online Library
Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for
patients with glioblastoma, the most aggressive glioma, although individually variable, has …

What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas?

CG Hadjipanayis, G Widhalm, W Stummer - Neurosurgery, 2015 - journals.lww.com
The current neurosurgical goal for patients with malignant gliomas is maximal safe
resection of the contrast-enhancing tumor. However, a complete resection of the contrast-enhancing …

5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas

…, D Bozec, TM Busch, CG Hadjipanayis - Journal of neuro …, 2019 - Springer
Introduction Photodynamic therapy (PDT) is a two-step treatment involving the administration
of a photosensitive agent followed by its activation at a specific light wavelength for …

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC· 3): a multicentre …

…, JB Ashman, JP Bahary, CG Hadjipanayis… - The Lancet …, 2017 - thelancet.com
Background Whole brain radiotherapy (WBRT) is the standard of care to improve intracranial
control following resection of brain metastasis. However, stereotactic radiosurgery (SRS) to …

EGFRvIII antibody–conjugated iron oxide nanoparticles for magnetic resonance imaging–guided convection-enhanced delivery and targeted therapy of glioblastoma

CG Hadjipanayis, R Machaidze, M Kaluzova, L Wang… - Cancer research, 2010 - AACR
… Brain Tumor Foundation (CG Hadjipanayis), the Georgia Cancer Coalition, Distinguished
Cancer Clinicians and Scientists Program (CG Hadjipanayis), and the Dana Foundation (CG

[HTML][HTML] Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia

CG Hadjipanayis, MJ Bonder… - Small (Weinheim an …, 2008 - ncbi.nlm.nih.gov
Current magnetic-nanoparticle technology is challenging due to the limited magnetic properties
of iron oxide nanoparticles (IONPs). Increasing the saturation magnetization of magnetic …

5-ALA and FDA approval for glioma surgery

CG Hadjipanayis, W Stummer - Journal of neuro-oncology, 2019 - Springer
… Ezrin (NXDC), Hadjipanayis, and Stummer were made to address the unmet medical need,
efficacy, safety, and risk–benefit of 5-ALA for detection of malignant tissue during surgery …

[HTML][HTML] Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification

…, S Neill, CG Hadjipanayis - Annals of translational …, 2015 - ncbi.nlm.nih.gov
Background Traditional classification of diffuse infiltrating gliomas (DIGs) as World Health
Organization (WHO) grades II-IV is based on histological features of a heterogeneous …

Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy

…, A Bouras, M Kaluzova, CG Hadjipanayis - Expert review of …, 2012 - Taylor & Francis
… from the NIH (NS053454 to CG Hadjipanayis), the Georgia Cancer … to CG Hadjipanayis),
the Robbins Scholar Award (to CG Hadjipanayis) and the Dana Foundation (to CG Hadjipanayis

[HTML][HTML] Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles

…, A Bouras, R Machaidze, CG Hadjipanayis - Oncotarget, 2015 - ncbi.nlm.nih.gov
Malignant gliomas remain aggressive and lethal primary brain tumors in adults. The epidermal
growth factor receptor (EGFR) is frequently overexpressed in the most common malignant …